Apotex Health Corp.

As of June 30, 2026, Apotex Health Corp. carries a market capitalization of 7.40B, placing it among publicly traded companies globally. Its enterprise value stands at 10.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Apotex Health Corp.'s next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, Apotex Health Corp. has 228.50M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Apotex Health Corp. maintains a current ratio of 1.77, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 863.10, indicating elevated leverage, while an interest coverage ratio of 2.00 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 136,418.76 in revenue per employee across its workforce of 6,216.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Apotex Health Corp. recorded 25.21M in income tax expense.

These figures are as of the close on October 22, 2026.

These figures cover the twelve months ended June 30, 2026.

As of June 30, 2026, Apotex Health Corp. holds 258.76M in cash and equivalents against 3.02B in total debt, resulting in a net debt position of 2.17B. Total book value stands at 350.19M, with working capital of 1.07B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026. After subtracting -61.67M in capital expenditures, free cash flow totaled -32.37M - equivalent to -0.16 per share.

Over the twelve months ended June 30, 2026, Apotex Health Corp. posted a gross margin of 49.67, reflecting its pricing power and cost economics. The operating margin of 10.22 and net profit margin of -4.52 provide insight into operational efficiency.